Solid Biosciences Inc (SLDB) Options

Question is when will the board become alive again. PPS wont be at 5$. Super discount.

SLDB under $6

elevated volume in recent sessions due to the gene therapy buzz.
Im surprised its yet a buzz
AAV capsid ... enhanced muscle tropism. Will work in DMD.
The first rally was sparked on IND clearance and fast track designation... From 2 - 14?? I believe what they saw instead was the platform working.

good bar and readouts due, maybe a rally starting.
Do your DD on LLYs Prevail breaking up with Precision.. which tried to -- you guessed it -- precisely edit the dystrophin itself... That doesnt work. Thats how you open pandoras box!

The SLDB AAV capsid platform does work -- Recent Uniqure and Capsida results should have helped the case on AAV capsid.
This one is engineered to go into the skeletal muscle no safety issues....

one of the few high institutional own names in the bio space that i like.
This one is going to moon on the platform and Duchenne ph1/2 data in late 2024/2025. This AAV capsid platform WORKS!! Company teamed up with Avanti to bring the platform to Friedreichs Ataxia too. They didnt want anything from them other than adopting the trial....
this will bring huge benefit to DMD and FA patients.

SLDB under $10

SLDB 10Q expected AUGUST 19 per Seeking Alpha

SLDB 10Q due MONDAY AUGUST 12 per Seeking Alpha

SLDB under $10

sadly traders are obsessed with finding the next best thing rather than the best next thing.
Listen to whats being SAID.... Outpacing all the others in the recovery rally

Going up on low volume
LONG overdue

I love LLY, i have this perspective.
I grow a garden of plants, collect my seeds and see them grow(SLDB)..... Then feed them to the big ponies (LLY)

I bought shares of Ely Lily when it was reaching new highs last September
The question now is will the board declare a forward split

LLYs Prevail dropped deal with Precision in Duchenne in April. Prevail, on their website, pretty much now mentions the superiority of SLDBs AAV approach. SLDB would perfectly fit into LLY/Prevails pipeline as their product trumps that of Precision...... and we know that they are looking for something in Duchenne. I actually believe they dropped the Prevail/Precision partnership after they saw what SLDB can do.

https://www.fiercebiotech.com/biotech/lillys-prevail-walks-away-gene-editing-collab-precision
https://www.prevailtherapeutics.com/programs/#our-pipeline
https://www.prevailtherapeutics.com/our-science/#overview

SLDB under $10

When an IND clearance and fast track designation spark a rally from 2 - 14$... You listen to what is happening/being said???
Apathic-to-life-excitement-traders dont want to know none of that.

"[...] Emil D. Kakkis, MD, PhD, Chief Executive Officer and President of Ultragenyx. “By using an AAV8 variant validated in prior human and other studies combined with our scalable, efficient HeLa producer cell line platform, we believe we can leverage our mutual strengths to develop a high-quality AAV-based treatment alternative for Duchenne.”

https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-and-solid-biosciences-announce-strategic

Please read about their work in DMD (and FA)-- very interesting. With their platform, they might treat both.
Groundbreaking for patients.
own 3000 shares

https://www.parentprojectmd.org/solid-biosciences-announces-updated-corporate-strategy-to-develop-sgt-001-and-sgt-003-pipeline-programs-for-patients-with-duchenne-muscular-dystrophy-2022/
they did this because they think the platform fixes FA and rare cardiomyopathies too....

https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.814174/full

SLDB over $10

SLDB 10Q due March 13

SLDB new 52 week hi

Thank you for your alerts, monk.

I'm on trading hiatus as I move a warehouse across country

But I'll be very receptive to these alerts, when I jump back in.

Can't wait to!

MG

SLDB new 52 week high

SLDB new 52 week high

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

SLDB new 52 week high

SLDB $6.13 +79%

Alerted @ 9:04 this morning (at +11%)

SLDB - Was once a $600 stock. It has massive upside potential!

SLDB $5.14...+50%

HOD $5.73

Wow! This is HUGE news! Thank you.

Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
https://www.globenewswire.com/news-release/2023/12/07/2792478/0/en/Solid-Biosciences-Receives-FDA-Fast-Track-Designation-for-Duchenne-Muscular-Dystrophy-Gene-Therapy-SGT-003.html

https://finviz.com/quote.ashx?t=SLDB&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/SLDB

Private Placement 159,574,463 $0.47 0 $74,999,998 2022-9-30 7:00
Underwritten S-3 21,739,131 $5.75 0 $125,000,003 Jefferies, SVB Leerink, Piper Sandler, Chardan 2021-3-18 21:14
Private Placement 24,324,320 $3.70 0 $89,999,984 Barclays Aspire Capital, Bain, Boxer, EcoR1, Perceptive Advisors, RA Capital 2020-12-11 7:30
Private placement 7,825,797 $5.11 0 $40,000,000 2020-10-23 0:00

SLDB +44%

SLDB 4.07 +0.65 (+19.00%)
As of 10:00AM EST.

SLDB May be worth monitoring for a move up today
https://stockcharts.com/h-sc/ui?s=SLDB

...I'm off to work!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173377749

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173377695

olid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
– Planning to initiate Phase 1/2 trial in pediatric DMD Patients –

– First cohort to study patients 4 to < 6 years of age –

CHARLESTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has received U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SGT-003, the company’s next-generation Duchenne Muscular Dystrophy (Duchenne) gene therapy candidate.

“We are pleased to have the FDA’s clearance to proceed into the clinic with SGT-003, a new, innovative gene therapy candidate for Duchenne,” said Bo Cumbo, President and CEO at Solid Biosciences. “SGT-003 combines our differentiated microdystrophin transgene with a next generation muscle-tropic capsid and a transient transfection manufacturing process that may help address the unmet needs for the Duchenne community.” Jessie Hanrahan Ph.D. Chief Regulatory Officer added “We appreciate the FDA’s review of the IND and look forward to continuing to work in collaboration with the agency when we initiate dosing of DMD patients.”

SGT-003 uses a proprietary, rationally designed capsid (AAV-SLB101) to deliver a DNA sequence encoding a shortened form of the dystrophin protein (microdystrophin), containing the R16 and R17 nNos binding protein domains. Preclinical data suggests this may be important for both muscular function and durability of benefit in patients.

“IND clearance for SGT-003 is a critical step in bringing a potential next generation gene therapy to the clinic and making a meaningful impact on the lives of those living with Duchenne. We are working closely with clinical sites to dose the first participants, driven by the belief that better therapies are urgently required to treat this devastating disease,” said Gabriel Brooks, M.D., Chief Medical Officer at Solid Biosciences.

Based on the clearance, Solid plans to move expeditiously to submit the study for IRB approval at the clinical trial sites and expects to commence patient screening shortly thereafter. The planned Phase 1/2 trial, SGT-003-101, is a first in human, open-label, multicenter trial to determine the safety and tolerability of SGT-003 in pediatric patients with DMD at a dose of 1E14vg/kg. SGT-003 will be administered as a one-time intravenous infusion to patients in two cohorts with a minimum of three patients each, with the potential for cohort expansion. Cohort 1 will study patients aged 4 to < 6 years of age with DMD. Long-term safety and efficacy will be evaluated for a total of 5 years following treatment.

In an mdx mouse model of Duchenne, SGT-003 demonstrated rapid transduction, showing robust microdystrophin expression levels in the heart, quadriceps, and diaphragm by day 4 post-gene therapy treatment. SGT-003 in nonhuman primates was shown to increase biodistribution to cardiac and skeletal muscle including the diaphragm versus AAV9. These studies suggest increased transgene expression and an improved safety profile compared to first generation microdystrophin gene therapies.

About DMD
Duchenne is a genetic muscle-wasting disease predominantly affecting boys, with symptoms usually appearing between three and five years of age. Duchenne is a progressive, irreversible, and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has an estimated prevalence of 5,000 to 15,000 cases in the United States alone.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates and neuromuscular and cardiac programs, including SGT-003, for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, AVB-202-TT for the treatment of Friedreich’s ataxia, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the company; the ability to successfully achieve and execute on the company’s priorities and achieve key clinical milestones; the company’s SGT-003 program, including expectations for working closely with the FDA and clinical sites, initiating dosing, increasing durability and expression, improving safety, developing an innovative therapy and meeting unmet need; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the ability to recognize the anticipated benefits of Solid’s acquisition of AavantiBio; the company’s ability to advance SGT-003, SGT-501, AVB-401, AVB-202-TT and other preclinical programs and capsid libraries on the timelines expected or at all; obtain and maintain necessary approvals from the FDA and other regulatory authorities; replicate in clinical trials positive results found in preclinical studies of the company’s product candidates; obtain, maintain or protect intellectual property rights related to its product candidates; compete successfully with other companies that are seeking to develop Duchenne and other neuromuscular and cardiac treatments and gene therapies; manage expenses; and raise the substantial additional capital needed, on the timeline necessary, to continue development of SGT-003, SGT-501, AVB-401, AVB-202-TT and other candidates, achieve its other business objectives and continue as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of

SLDB

!5 = 1 RS. 42 = 6.30. Will it hold?

SLDB

SLDB looking for a run up tomorrow, should move after consolidating today

SLDB chart

* * $SLDB Video Chart 02-23-2021 * *

Link to Video - click here to watch the technical chart video

SLDB on Dec 4th was $3.63 today Jan 5th $7.61 works for me.
Thanks to the select group of institutional investors and accredited investors for a $90 million private placement!

Glad I bought in after the $90 Million private placement. Solid BIO doing really well !

I don't care about changing your mind. I really couldn't care less what you think of the company. I'm not trying to convince other people about the company either. I'm stating what's going on here based on my interpretation of the facts that are publicly available. The share price is much too high right now to buy it. I'd buy if it ever hits $4.00 again, but probably not before. There are many other stocks out there that currently have a better risk/reward profile than this does, and I'm buying them.

There's nothing you can say that will change my mind that this company is a pump-and-dump. You should use your energy to convince other people about this company.

Let it go.

I'm not sure in what way it is recognizable, but it is interesting that you think so. We should agree to disagree. Oddly enough, I haven't invested in this yet - I was thinking about it at $3.70, as Ultragenyx clearly knew what they were doing putting in $40 million at $5.11, but I thought I had more time before they developed further. The $90 million investment at $3.70 changed the whole game, and now the floor is clearly $3.70 unless they have a developmental mishap. I think it's overpriced right now, but when the flurry of activity dwindles and it slowly sinks back toward $4.00 assuming the absence of any major near-term news, I could be very interested in getting in dependent on their future progress.

Your defense of the company is recognizable. Which is questionable.

I think this company is a scam.
You think the company is not a scam.
And that's where it ends.

Good luck in your investment with this company.
But I'll pass.

The impression you should be getting is that of a person who knows how to analyze publicly-available information and make informed conclusions. I've seen more POS stocks in my investing experience on these boards of the type with which you are apparently familiar than I can count, and I can tell you that this is not one of them.

I'm starting to get the impression you're a stock promoter for the company.

* * $SLDB Video Chart 12-15-2020 * *

Link to Video - click here to watch the technical chart video

On what information do you base your allegations? Have you read the publicly-available information? By rule of logic then, the reverse scamming must have pulled it up to over $6 so far today.